Christopher G. Bunick, MD, PhD

Join Dermatology Times’ quarterly editor in chief Christopher Bunick, MD, PhD, as he discusses transformative advances in psoriasis care.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.

Christopher Bunick, MD, PhD, reviews the latest findings on benzene in benzoyl peroxide, highlighting the importance of proper storage and patient safety.

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

Key opinion leaders examine upadacitinib's role in managing atopic dermatitis and its impact on improving patients' quality of life.

Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.

Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.

Medical experts examine the practical application of clinical study results to real-world atopic dermatitis management strategies.

Atopic dermatitis experts evaluate the integration of composite scores and quality of life measures as a new benchmark for comprehensive disease management.

Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.

By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief in atopic dermatitis.

Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.

Christopher Bunick, MD, PhD, expands on how clinicians can personalize treatment plans for each patient.

Christopher Bunick, MD, PhD, reviews benchmarks for optimal outcomes in patients with atopic dermatitis and compares treatments available.

In our March publication, Winter Editor in Chief Christopher Bunick, MD, PhD, delved into the growing concern of benzene in personal care products. This commentary becomes all the more important in light of the recent findings of high levels of benzene in acne products.

Star Trek may call space “the final frontier,” but it’s really the next exciting frontier for humans. For now, we can learn about the various new innovations and therapies for skin disease at the AAD annual meeting—and continue to strive to improve our patients’ lives here on Earth.

Winter Editor in Chief Christopher Bunick, MD, PhD, looks ahead to a year of dermatology innovations with a reflection on meaningful advances from 2023.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.

Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).